Suppr超能文献

贝克威斯-威德曼综合征患者血清甲胎蛋白参考范围的建立。

Development of the Serum α-Fetoprotein Reference Range in Patients with Beckwith-Wiedemann Spectrum.

机构信息

Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA.

Biostatistics and Data Management Core, Children's Hospital of Philadelphia, Philadelphia, PA; Westat, Rockville, MD.

出版信息

J Pediatr. 2019 Sep;212:195-200.e2. doi: 10.1016/j.jpeds.2019.05.051. Epub 2019 Jun 22.

Abstract

OBJECTIVE

To establish reference ranges for serum α-fetoprotein (AFP) at various ages in patients with Beckwith-Wiedemann spectrum (BWSp), to better predict the risk for hepatoblastoma in this population.

STUDY DESIGN

A retrospective analysis of AFP measurements collected from patients with BWSp was performed. Factors including sex, prematurity, molecular diagnosis of patients, and performing laboratory were evaluated for significant differences. In total, 1372 AFP values were collected from 147 patients and the predictive AFP values at various ages were calculated to establish reference ranges. Mixed-effects polynomial regression models were used to study various potential factors affecting log(AFP) values.

RESULTS

Overall, predicted AFP values declined to normal range for age (<10 ng/mL) by 14 months old. Patient sex and performing laboratory were found not to influence values. A significant difference was demonstrated between premature and nonpremature patients, and separate reference values were established. Significant differences in the predicted AFP value were not broadly apparent between molecular subtypes; however, interpretation was limited due to the small sample size of some of these subtypes.

CONCLUSIONS

Predictive AFP values were created for premature and nonpremature patients with BWSp to aid with interpretation and monitoring of the risk for hepatoblastoma. Further analysis is needed to determine whether AFP values differ within the less common molecular subtypes of patients with BWSsp.

摘要

目的

建立 Beckwith-Wiedemann 谱(BWSp)患者各年龄段血清甲胎蛋白(AFP)的参考范围,以便更好地预测该人群中肝母细胞瘤的风险。

研究设计

对 BWSp 患者 AFP 测量值进行回顾性分析。评估了性别、早产、患者的分子诊断和实验室检测等因素是否存在显著差异。共收集了 147 名患者的 1372 个 AFP 值,并计算了各年龄段的预测 AFP 值,以建立参考范围。使用混合效应多项式回归模型研究了各种可能影响 log(AFP)值的因素。

结果

总体而言,预测的 AFP 值在 14 个月时降至正常年龄范围(<10ng/mL)。患者性别和实验室检测结果未显示对值有影响。早产和非早产患者之间存在显著差异,建立了单独的参考值。尽管由于某些亚型的样本量较小,对分子亚型之间的预测 AFP 值差异没有广泛的认识,但解释受到限制。

结论

为 BWSp 早产儿和非早产儿创建了预测 AFP 值,以帮助解释和监测肝母细胞瘤的风险。需要进一步分析以确定 BWSp 患者中较不常见的分子亚型的 AFP 值是否存在差异。

相似文献

1
Development of the Serum α-Fetoprotein Reference Range in Patients with Beckwith-Wiedemann Spectrum.
J Pediatr. 2019 Sep;212:195-200.e2. doi: 10.1016/j.jpeds.2019.05.051. Epub 2019 Jun 22.
2
Defining an optimal time window to screen for hepatoblastoma in children with Beckwith-Wiedemann syndrome.
Pediatr Blood Cancer. 2019 Jan;66(1):e27492. doi: 10.1002/pbc.27492. Epub 2018 Sep 30.
3
The utility of alpha-fetoprotein screening in Beckwith-Wiedemann syndrome.
Am J Med Genet A. 2017 Mar;173(3):581-584. doi: 10.1002/ajmg.a.38068. Epub 2017 Feb 4.
5
Serum alpha-fetoprotein levels in Beckwith-Wiedemann syndrome.
J Pediatr. 2000 Jul;137(1):123-7. doi: 10.1067/mpd.2000.106217.
6
Alpha-fetoprotein (AFP) levels in normal children.
Eur J Pediatr Surg. 1997 Oct;7(5):267-9. doi: 10.1055/s-2008-1071168.
7
Serum alpha-fetoprotein screening for hepatoblastoma in Beckwith-Wiedemann syndrome.
Am J Med Genet A. 2017 Mar;173(3):585-587. doi: 10.1002/ajmg.a.38077.
8
Serum α-fetoprotein concentration in extremely low-birthweight infants.
Pediatr Int. 2017 Feb;59(2):159-162. doi: 10.1111/ped.13090. Epub 2016 Nov 10.
9
Hepatoblastoma associated with Beckwith-Wiedemann syndrome and hemihypertrophy.
Pediatr Surg Int. 2003 Apr;19(1-2):112-4. doi: 10.1007/s00383-002-0734-2. Epub 2003 Mar 2.
10
Experience with hemihyperplasia and Beckwith-Wiedemann syndrome surveillance protocol.
Am J Med Genet A. 2009 Aug;149A(8):1691-7. doi: 10.1002/ajmg.a.32966.

引用本文的文献

2
Hepatoblastoma.
Nat Rev Dis Primers. 2025 May 22;11(1):36. doi: 10.1038/s41572-025-00620-7.
5
Epigenetics and genetics of hepatoblastoma: Linkage and treatment.
Front Genet. 2022 Nov 30;13:1070971. doi: 10.3389/fgene.2022.1070971. eCollection 2022.
6
Hepatoblastoma in molecularly defined, congenital diseases.
Am J Med Genet A. 2022 Sep;188(9):2527-2535. doi: 10.1002/ajmg.a.62767. Epub 2022 Apr 28.
7
Lateralized and Segmental Overgrowth in Children.
Cancers (Basel). 2021 Dec 7;13(24):6166. doi: 10.3390/cancers13246166.
8
Diagnosis and Management of Beckwith-Wiedemann Syndrome.
Front Pediatr. 2020 Jan 21;7:562. doi: 10.3389/fped.2019.00562. eCollection 2019.
9
Characterization of the Beckwith-Wiedemann spectrum: Diagnosis and management.
Am J Med Genet C Semin Med Genet. 2019 Dec;181(4):693-708. doi: 10.1002/ajmg.c.31740. Epub 2019 Aug 30.

本文引用的文献

1
Defining an optimal time window to screen for hepatoblastoma in children with Beckwith-Wiedemann syndrome.
Pediatr Blood Cancer. 2019 Jan;66(1):e27492. doi: 10.1002/pbc.27492. Epub 2018 Sep 30.
3
Tumor Screening in Beckwith-Wiedemann Syndrome: Parental Perspectives.
J Genet Couns. 2018 Aug;27(4):844-853. doi: 10.1007/s10897-017-0182-8. Epub 2017 Dec 4.
4
5
Nomenclature and definition in asymmetric regional body overgrowth.
Am J Med Genet A. 2017 Jul;173(7):1735-1738. doi: 10.1002/ajmg.a.38266. Epub 2017 May 5.
6
Serum alpha-fetoprotein screening for hepatoblastoma in Beckwith-Wiedemann syndrome.
Am J Med Genet A. 2017 Mar;173(3):585-587. doi: 10.1002/ajmg.a.38077.
7
The utility of alpha-fetoprotein screening in Beckwith-Wiedemann syndrome.
Am J Med Genet A. 2017 Mar;173(3):581-584. doi: 10.1002/ajmg.a.38068. Epub 2017 Feb 4.
8
Tumor screening in Beckwith-Wiedemann syndrome-To screen or not to screen?
Am J Med Genet A. 2016 Sep;170(9):2261-4. doi: 10.1002/ajmg.a.37881.
9
Phenotype, cancer risk, and surveillance in Beckwith-Wiedemann syndrome depending on molecular genetic subgroups.
Am J Med Genet A. 2016 Sep;170(9):2248-60. doi: 10.1002/ajmg.a.37801. Epub 2016 Jul 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验